Oncology Practice Review – Issue 2

In this issue:
– Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for NSCLC
– ESMO kidney cancer guidelines 2024
– Global epidemiology of kidney cancer
– Failure to obtain successful bowel cancer screening in New Zealand: high-risk groups
– Complete cancer prevalence in Europe in 2020
– International guidelines on anal cancer screening
– Ponsegromab for the treatment of cancer cachexia
– Optimal time from colorectal cancer surgery to adjuvant chemotherapy
– Response to neoadjuvant immunotherapy predicts relapse free survival in patients with HCC
– Predicting chemotherapy toxicity from genomic variants
– Evolving landscape of tissue-agonist therapies
– First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer
– Cancer drug approvals in New Zealand in 2024
– HRC funds NZ research into cancer clinical trial access
– FDA approves first engineered T-cell receptor therapy for cancer
– Smoking more than doubles the lung cancer mortality risk after radiation for breast cancer
– ASCO releases first guidelines on use of cannabis/cannabinoids for cancer patients
– Hundreds of potential druggable targets identified by pan-cancer proteogenomics